Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition

Hepatocellular carcinoma (HCC) is a malignancy with high morbidity and mortality but lacks effective treatments thus far. Although the emergence of immune checkpoint inhibitors in recent years has shed light on the treatment of HCC, a considerable number of patients are still unable to achieve durab...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Rui, Ling, Changquan, Wang, Yuqian, Lu, Lingeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504701/
https://www.ncbi.nlm.nih.gov/pubmed/37716965
http://dx.doi.org/10.1186/s12935-023-03051-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504701/
https://www.ncbi.nlm.nih.gov/pubmed/37716965
http://dx.doi.org/10.1186/s12935-023-03051-0

Ejemplares similares